1 |
Wells G, Shea B, O'connell D, et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: Proc 3rd Symposium on Systematic Reviews, pp. 3-5, Oxford, UK,.
|
2 |
Xiao H, Ding J, Gao S, et al (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.
|
3 |
Yu C, Pan K, Xing D, et al (2002). Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res, 62, 6430-3.
|
4 |
Zhou Y, Yu C, Miao X, et al (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis, 26, 1117-21.
DOI
|
5 |
Aysegul B, Veysi GH, Muzaffer M, et al (2011). Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? Mol Biol Rep, 38, 1469-74.
DOI
|
6 |
Bauvois B (2012). New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta, 1825, 29-36.
|
7 |
Brennan P, Hainaut P, Boffetta P (2011). Genetics of lung-cancer susceptibility. Lancet Oncol, 12, 399-408.
DOI
|
8 |
Cao XL, Xu RJ, Zheng YY, et al (2011). Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev, 12, 3245-9.
|
9 |
Chetty C, Rao JS, Lakka SS (2011). Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics, 12, 535-46.
DOI
|
10 |
Decock J, Paridaens R, Ye S (2008). Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet, 73, 197-211.
|
11 |
DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
DOI
|
12 |
Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74.
DOI
ScienceOn
|
13 |
Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, et al (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer, 12, 121.
DOI
|
14 |
Hahn N, Heiden M, Seitz R, et al (2012). Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion. J Cancer Res Clin Oncol, 138, 695-703.
DOI
|
15 |
Herbst RS, Heymach JV, Lippman SM (2008). Lung cancer. N Engl J Med, 359, 1367-80.
DOI
ScienceOn
|
16 |
Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
DOI
ScienceOn
|
17 |
Im I, Park KR, Kim SM, et al (2012). The butanol fraction of guava (Psidium cattleianum Sabine) leaf extract suppresses MMP-2 and MMP-9 expression and activity through the suppression of the ERK1/2 MAPK signaling pathway. Nutr Cancer, 64, 255-66.
DOI
|
18 |
Ioannidis JP, Patsopoulos NA, Evangelou E (2007). Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335, 914-6.
DOI
|
19 |
Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
20 |
Jia S (2009) MMP-2 and TIMP-2 polymorphisms and lung cancer risk. In: 5th National Medical immune Symposium.
|
21 |
Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
|
22 |
Nelson AR, Fingleton B, Rothenberg ML, et al (2000). Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol, 18, 1135-49.
|
23 |
Peters J, Mengersen K (2008). Selective reporting of adjusted estimates in observational epidemiology studies: reasons and implications for meta-analyses. Eval Health Prof, 31, 370-89.
DOI
|
24 |
Price S, Greaves D, Watkins H (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549.
DOI
ScienceOn
|
25 |
Rollin J, Regina S, Vourc'h P, et al (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56, 273-80.
DOI
|
26 |
Song X, Li L, Zhang L, et al (2007). Association Polymorphisms in the Matrix Metalloproteinases-2(MMP-2) Gene with Non-small Cell Lung Cancer. Sichuan Cancer Prevention Treatment, 20, 257-9.
|
27 |
Wang Y, Hu C, Dong R, et al (2011). Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9. Asian Pac J Cancer Prev, 12, 3367-70.
|